5 Nahum Heftsadie Street
Givaat Shaul
Jerusalem 91340
Israel
972 2 659 5666
https://www.gamida-cell.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 166
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Julian Adams Ph.D. | CEO & Director | 707k | N/A | 1955 |
Mr. Shai Lankry CPA, M.B.A. | Chief Financial Officer | 564k | N/A | 1976 |
Ms. Michele Ilene Korfin M.B.A., R.Ph. | Chief Operating & Chief Commercial Officer | 510k | N/A | 1972 |
Dr. Ronit Simantov M.D. | Chief Medical & Chief Scientific Officer | 581k | N/A | 1965 |
Dr. Jas Uppal | Chief Regulatory & Quality Officer | 476k | N/A | 1968 |
Mr. Joshua F. Patterson | Gen. Counsel & Chief Compliance Officer | N/A | N/A | 1976 |
Mr. Paul Nee | VP of Marketing | N/A | N/A | N/A |
Mr. Naftali Brikashvili CPA | Sr. VP Fin. & Operations | N/A | N/A | N/A |
Dr. Tracey Lodie Ph.D. | Scientific Advisor & Consultant | N/A | N/A | 1970 |
Mr. Vladimir Melnikov | Sr. VP of Global Operations & Manufacturing | N/A | N/A | N/A |
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Gamida Cell Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.